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ABSTRACT
Introduction: Although insulin is one of the
most effective interventions for the treatment
of type 2 diabetes, its disadvantages incur
substantial medical cost. This study was
designed to evaluate the medical costs of
Swedish type 2 diabetic patients initiating
insulin on top of metformin and/or
sulfonylurea (SU), and to evaluate if costs
before and after insulin initiation differ for
patients where insulin is initiated above or
below the recommended glycosylated
hemoglobin (HbA1c) level (7.5%).
Methods: This was a register-based
retrospective cohort study in which patients
were identified from the So¨rmland county
council diabetes register. Patients being
prescribed at least one prescription of
metformin and/or SU from 2003 to 2010, and
later prescribed insulin, were included.
Results: One hundred patients fulfilled the
inclusion criteria and had at least 1 year of
follow-up. The mean age was 61 years and 59%
of patients were male. Mean time since
diagnosis was 4.1 years, and since initiation of
insulin was 2.2 years. The mean HbA1c level at
index date was 8.0%. Total mean costs for the
whole cohort were SEK 17,230 [standard
deviation (SD) 17,228] the year before insulin
initiation, and SEK 31,656 (SD 24,331) the year
after insulin initiation (p\0.0001). When
stratifying by HbA1c level, patients with
HbA1c \7.5% had total healthcare costs of SEK
17,678 (SD 12,946) the year before the index
date and SEK 35,747 (SD 30,411) the year after
(p\0.0001). Patients with HbA1c levels C7.5%
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had total healthcare costs of SEK 16,918
(SD 19,769) the year before the index date and
SEK 28,813 (SD 18,779) the year after
(p\0.0001).
Conclusion: Despite the small sample size, this
study demonstrates that mean annual medical
costs almost double the year after patients are
initiated on insulin. The costs increased the year
after insulin initiation, regardless of the HbA1c
level at initiation of insulin, and the largest
increase in costs were due to increased filled
prescriptions.
Keywords: Cohort study; Cost; Insulin;
Sweden; Type 2 diabetes
INTRODUCTION
In Sweden, the prevalence of diabetes mellitus
has recently been estimated to be 4.4% among
the adult population, with type 2 diabetes
accounting for approximately 90% of all cases
[1]. As diabetes is a major cause of morbidity
and premature mortality, the disease has a
significant impact on healthcare costs and
quality of life (QoL) [2, 3].
It is well established that adequate glycemic
control [glycosylated hemoglobin (HbA1c)
below 6.5–7%] reduces the risk of diabetes-
related complications, and this is therefore the
key goal in management of type 2 diabetes [4].
Insulin is one of the most effective HbA1c-
lowering interventions and, due to the
progressive nature of type 2 diabetes at higher
HbA1c-levels, insulin may be the only treatment
option for many patients [5]. According to the
Swedish National Board of Health and Welfare’s
clinical guidelines on management of type 2
diabetes [6], the first preventive measure to
decrease HbA1c is lifestyle intervention and
later initiation of metformin. When these
measures fail to control glucose levels and the
HbA1c-level rises to 7.5%, treatment with a
sulfonylurea (SU) or insulin should be initiated.
There are alternative approved treatment
options that may be initiated before
prescribing insulin, if HbA1c levels are \7.5%
and the patient does not respond to metformin,
including sitagliptins and GLP-1 receptor
antagonists. However, many physicians choose
to initiate insulin before the patient has reached
an HbA1c level of 7.5%. Insulin treatment has a
number of disadvantages, such as weight gain,
reaction from the injection and hypoglycemia
[7], and in particular during the early period of
initiating insulin, patients most likely show
psychologic insulin resistance [8] resulting in
complications and increased healthcare costs.
Although there are a number of published
studies evaluating the costs of Swedish patients
with type 2 diabetes [9–11], there are to our
knowledge no Swedish studies comparing the
costs of pre- and post-initiation of insulin.
There is also little evidence when stratifying
annual medical costs before and after initiation
of insulin in patients with HbA1c-level of
\7.5%, where other treatment options are still
available, versus HbA1c-level C7.5%. The aims
of this study were to evaluate the healthcare
costs of patients with type 2 diabetes initiating
insulin on top of metformin and/or SU, and to
understand if these costs differ if the patient has
reached HbA1c levels of 7.5% or not. If the
results from this study indicate that treatment
with insulin on top of metformin is related to
substantially higher healthcare costs compared
with treatment with metformin and/or SU
alone, this could be an indication that other
oral anti-diabetic drugs (OADs) apart from
metformin could be favored while HbA1c is
still below critical levels. This could have an
impact both in terms of savings of healthcare
resources and on patients’ QoL.
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METHODS
This study is a register-based retrospective
cohort study including Swedish patients with
type 2 diabetes who started treatment with
metformin and/or SU and were later prescribed
insulin.
Study Population
All patients were identified from the So¨rmland
county council diabetes register. The register
includes information on patients with type 2
diabetes receiving treatment within the county
council from 2003 to 2004 onwards, as well as
information on caregiver contacts, laboratory
tests (including HbA1c values), diagnoses,
procedures, prescribed drugs, and
demographics. Information on filled
prescriptions and devices were retrieved from
the prescribed drug register, which is a national
register held at the National Board of Health
and Welfare containing information on all
prescribed medicines and pharmaceutical aids
dispensed at Swedish pharmacies since June
2005. Information on mortality during the
follow-up period was retrieved from the cause
of death register at the National Board of Health
and Welfare. The register includes nationwide
data since 1961 and includes underlying and
contributory causes of death according to the
International Classification of Disease (ICD)
system. This study included all patients in the
diabetes register identified as being prescribed at
least one prescription of metformin and/or SU
from 2003 to 2010 and later prescribed
treatment with insulin. Patients were excluded
from the study if they were being prescribed
insulin before June 2005, had an initial
diagnosis of type 1 diabetes, had records of
prescriptions of OADs other than metformin or
SU prior to the index date, or if they had no
records of metformin or SU prior to the index
date.
After approval from an ethical committee,
data were extracted from the diabetes register
based on the inclusion criteria and linked to the
administrative registers at the National Board of
Health and Welfare through the patients’
national registration number. All identifiable
data were replaced with new study IDs to de-
identify the data.
For each identified patient, the index date
was defined as the date of the first insulin
prescription in the diabetes register during the
period January 1, 2005 through December 31,
2009. The HbA1c level at initiation of insulin
used in the stratified analysis was chosen as the
last HbA1c lab value measured prior to the
index date. The aim was to choose a value
measured within 1 month and not longer than
3 months before insulin initiation.
HbA1c was measured using the Mono-S
method [12]. For conversion to measurements
with the DCCT/NGSP method, the following
conversion formula may be used: HbA1c (NGSP)
(%) = 0.956 9 HbA1c (Mono S) (%) ? 1.182 (see
e.g., http://www.hba1c.nu/).
Annual medical costs were computed from
the third party payer perspective for healthcare
visits, treatment interventions, and procedures
(described as DRG) and prescriptions of anti-
glycemic medications, diabetic devices, and
aids. For the purpose of estimating costs
incurred in the management before and after
the initiation of insulin, unit costs for
individual procedures were derived based on
DRG-codes in the diabetes register. Unit costs
for healthcare resources were obtained through
three different county council lists for costs and
calculated as a mean of the three measures
(including Skane county [13], Vastragotaland
region county council [14] and Norrlands lans
county council [15]) according to Swedish
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standards. These unit costs varied by resource
use, and were applied to the resource utilization
items, which were used to calculate the overall
medical costs of healthcare utilization. Costs for
prescribed drugs were primarily based on the
information from the prescribed drug register
including updated information on national
costs from the latest reference year. Costs were
calculated on an individual basis by summing
the products of unit costs with quantities of
different types of resources consumed and
presented as means for all patients. The latest
reference year for unit costs was used (SEK 2012;
1 € = 8.4 SEK on March 25, 2013).
Analyses were conducted using patient-level
data, but all reporting was on an aggregated
level. All data management and statistical
analyses were performed using SAS 9.2 (SAS
Institute Inc., Cary, NC, USA).
Statistical Considerations
The resource use items available within this
study were visits to primary care, outpatient
admissions to medical wards, surgeries and
procedures through DRG-codes, prescription
pharmaceuticals, and devices for glucose-
monitoring and insulin administration.
Annual quantities of these resource items
during the 12-month post-initiation of insulin
were determined for each patient. Healthcare
costs during the 12-month post-initiation of
insulin were estimated by multiplying
quantities of resource use by unit costs from
published sources. Similarly, annual quantities
of resource use during the year pre-initiation of
insulin were determined for each patient, and
corresponding healthcare costs were estimated
by multiplying quantities of resource use with
unit costs.
Descriptive statistics on an aggregated level
were used to present patient characteristics,
resource utilization, and costs for all patients
in the dataset. For continuous variables, the
arithmetic mean, standard deviation (SD),
minimum, and maximum are presented. For
categorical variables, the proportions
(percentage) in each category are presented.
The normality of the distributions was tested
employing the Shapiro–Wilks test and by
plotting the data. If found not to be normally
distributed, means and SD were estimated using
the bias corrected accelerated bootstrapping
method with replacement. To test differences
between costs before and after the index date, a
t test was used to measure if the difference
between the two costs was separated from zero.
There were no missing values in the dataset and
imputation of missing data was not necessary.
Variables describing patient characteristics
included age at the index date, sex, height,
weight, co-morbidities, HbA1c level at the index
date, systolic blood pressure at the index date,
and diastolic blood pressure at the index date.
The estimated healthcare costs were
subsequently stratified by HbA1c level at index
date and statistical tests were used to compare
costs pre- and post-initiation of insulin for each
HbA1c-group separately (Group 1\7.5%, Group
2 C7.5%).
RESULTS
The selection of patients is presented in Fig. 1.
In total, 667 patients initiated on insulin during
the study period were identified and extracted
from the diabetes register. After removing
patients who had been treated with OADs
other than metformin or SU prior to the index
date, had a primary diagnosis of type 1 diabetes,
had been prescribed insulin prior to the index
date, had not been prescribed metformin or SU
prior to the index date, and had \365 days
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follow-up before or after the index date, 100
patients were eligible for the analysis.
Patient Characteristics
Patient characteristics are demonstrated in
Table 1. The mean age of the patients was 64
(SD 10) years, ranging from 35 to 80 years. Most
patients were men (n = 59, 59%).
There were 41 patients who were initiated on
insulin at HbA1c levels \7.5%, and 59 patients
at Hba1c levels C7.5%. Patient characteristics
comparing patients with HbA1c level \7.5%
and C7.5% at the index date are shown in
Table 2. Patients with HbA1c levels\7.5% were
older than those with HbA1c levels C7.5% at
the index date [67 (SD 7) vs. 63 (SD 11) years,
p = 0.051]. The mean HbA1c level at the index
date was 6.7% (SD 0.7%) among the HbA1c level
\7.5% group and 8.9% (SD 1.6%) among the
HbA1c C7.5% group (p = 0.0001). There was
also a statistically significant difference between
the two groups in terms of diastolic blood
pressure [77.2 mmHg (SD 9.1) vs. 82.1 mmHg
(SD 11.3), p = 0.018]. Even though total number
of co-morbidities did not differ between the two
groups, patients with HbA1c levels\7.5% had a
higher number of cardiovascular events (see
Table 3).
Costs
Total medical costs for the total cohort, and
stratified by HbA1c-level, are shown in Tables 4
and 5, respectively.
The total medical healthcare costs for the
entire cohort the year before initiation of
insulin (Table 4) were SEK 17,230 (SD 17,228),
and the year after were SEK 31,656 (SD 24,331)
(p\0.0001). The highest proportion of costs
before the index date was as a result of visits to
primary care followed by costs due to visits to
medical wards, procedures and medications,
whilst the highest proportion after the index
Fig. 1 Patient exclusion. OAD oral anti-diabetic drugs, Met metformin, SU sulfonylurea, T1DM type 1 diabetes, T2DM
type 2 diabetes, DR diabetes register, PDR prescribed drug register
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date were due to medications, followed by visits
to primary care, visits to medical wards, and
procedures.
When stratifying total medical healthcare
costs by HbA1c group (Table 5), the group with
HbA1c levels \7.5% had total medical costs of
SEK 17,678 (SD 12,946) the year before the
index date, and SEK 35,747 (SD 30,411) the year
after the index date (p\0.0001). The group
with HbA1c levels C7.5% had total medical
costs of SEK 16,918 (SD 19,769) the year before
the index date and SEK 28,813 (SD 18,779) the
year after the index date (p\0.0001). In
patients with HbA1c levels \7.5%, the year
before initiation of insulin, the highest
proportion of costs was due to visits to
primary care, followed by costs due to visits to
medical wards, medications, and procedures.
The year after the index date, the highest costs
were due to medications, followed by costs due
to visits to primary care, visits to medical wards,
and procedures. In the group with HbA1c levels
C7.5% at the index date, the year before
initiation of insulin, the highest proportion of
costs was due to visits to primary care, followed
by costs due to visits to medical wards,
procedures, and medications. The year after
Table 1 Patient characteristics, all patients (n = 100)
Patient characteristics






HbA1c level at initiation of
insulin (%)
8 (1.7) [4.1–14]
Systolic blood pressure (mmHg) 141.1 (20.7)
[105–225]
Diastolic blood pressure (mmHg) 80.1 (10.7)
[50–110]





patients with HbA1c levels
\7.5% and C7.5% at
initiation of insulin












Age 67 (7) 63 (11) 0.051
Female, n (%) 10 (24) 24 (41) 0.091
Height 172 (9) 173 (12) 0.576
Weight 85 (16) 96 (27) 0.477
Disease description
Years since index date 2.2 (0.9) 2.2 (1.2) 0.69
Years since diagnosis 4.2 (0.9) 4.2 (1.2) 0.691
HbA1c level at initiation of insulin, % (±SD) 6.7 (0.7) 8.9 (1.6) \0.0001
Systolic blood pressure, mmHg (±SD) 138.4 (17.9) 142.9 (22.4) 0.482
Diastolic blood pressure, mmHg (±SD) 77.2 (9.1) 82.1 (11.3) 0.018
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the index date, the highest costs were due to
medications, followed by costs due to visits to
primary care, visits to medical wards, and
procedures.
The total medical costs due to health care
visits in the entire patient cohort were SEK
11,795 (SD 10,366) the year before the index
date and SEK 18,289 (SD 16,955) the year after
the index date (p\0.0001). The highest
proportion of this was due to visits to primary
care both before and after the index date [SEK
6,801 (SD 4,539) pre-index; SEK 10,486 (SD
7,202) post-index, p\0.0001]. The costs due to
visits to medical wards were SEK 4,994 (SD
9,565) the year before the index date and SEK
7,803 (SD 16,224) the year after the index date
(p = 0.039). Even though not statistically
significant, the costs related to visits to
medical wards included visits to physicians
and nurses, both before and after the index
date. There were no statistically significant
differences in mean costs the year before and
after the index date due to procedures.
There were no statistically significant
differences in costs due to health care visits
before and after the index date compared with
the year before the index date in patients with
HbA1c levels \7.5% at the index date
(p = 0.118). The mean total medical costs due
to health care visits were lower in the group
with HbA1c levels C7.5% at the index date
compared with the group with HbA1c levels
\7.5%, both the year before the index date [SEK
10,400 (SD 10,423)], and the year after [SEK
17,084 (SD 16,856)]. The total mean costs the
year after the index date were statistically
significantly higher than the year before
(p\0.0001). The highest proportion of these
Table 3 Cardiovascular events stratiﬁed by HbA1c level
at index date





Hypertension 21 (51) 39 (66)
Hypertensive heart and
renal disease
2 (5) 2 (3)
Angina pectoris 4 (10) 9 (15)
Myocardial infarction 2 (5) 1 (2)
Ischemic heart disease 8 (20) 10 (17)
Heart failure 9 (22) 5 (8)
Intracerebral hemorrhage 0 (0) 3 (5)
Chronic kidney disease 0 (0) 2 (3)
Total 46 71
Table 4 Total annual per patient medical healthcare costs (SEK) before and after 1 year of initiation of insulin (n = 100)
Cost (SEK) Pre-index date Post-index date p value*
Mean SD Mean SD
Healthcare visits 11,795 10,366 18,289 16,955 \0.0001
Visits to primary care 6,801 4,539 10,486 7,202 \0.0001
Visits to medical ward 4,994 9,565 7,803 16,224 0.039
Procedures 2,895 11,666 2,845 12,639 1.000
Filled prescriptions 2,540 1,929 10,522 5,624 \0.0001
Total costs 17,230 17,228 31,656 24,331 \0.0001
SD standard deviation
* t test
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costs were due to visits to primary care [SEK
6,302 (SD 4,776) pre-index; SEK 10,823 (SD
7,898) post-index, p\0.0001], whereas the
costs due to visits to medical wards incurred
SEK 4,098 (SD 9,268) the year before the index
date and SEK 6,262 (SD 16,296), the year after
the index date (p = 0.711).
In the total cohort, there was a statistically
significant increase in mean total medical costs
related to filled prescriptions the year after the
index date [SEK 10,522 (SD 5,624)] compared
with the year before the index date [SEK 2,540
(SD 1,929); p\0.0001]. The highest mean costs
related to insulin devices and aids were due to
test sticks both before and after the index date
[SEK 1,447 (SD 1,554) pre-index; SEK 3,342 (SD
3,290) post-index; p\0.0001] (data not
presented in the table).
The total mean costs due to filled
prescriptions among the HbA1c \7.5% group
were statistically significantly higher the year
after the index date compared with the year
before the index date [SEK 3,024 (SD 2,306) pre-
index; SEK 9,732 (SD 4,657) post-index;
p\0.0001]. The same statistically significant
difference was seen in the group with HbA1c
levels C7.5% at the index date [SEK 2,203 (SD
1,551) pre-index; SEK 11,071 (SD 6,187) post-
index; p\0.0001].
DISCUSSION
This study aimed at estimating and comparing
annual medical costs the year before and after
initiation of insulin (index date) among
Swedish patients with type 2 diabetes. The
study also aimed at estimating these costs
stratified by HbA1c level at the date of
initiation of insulin, based on the
recommended cut-off level (HbA1c C7.5%).
Our results demonstrated almost doubled,
statistically significant increases in mean
annual costs the year after the initiation of
insulin compared with the year before. The
highest proportion of mean annual medical
costs was due to visits to primary care the year
before the index date, but shifted to costs due to
filled prescriptions the year after. This
demonstrates that filled prescriptions of
insulin have a significant impact on the total
medical costs. The increased costs of filled
prescriptions were also due to increased filled
Table 5 Total annual per patient medical healthcare costs (SEK) before and after 1 year of initiation of insulin stratiﬁed by
HbA1c-level at index date
Cost (SEK) HbA1c <7.5% (n5 41) HbA1c ‡7.5% (n5 59)
Pre-index date Post-index date Pre-index date Post-index date
Mean SD Mean SD p-value Mean SD Mean SD p value*
Healthcare visits 13,803 10,072 20,022 17,154 0.118 10,400 10,423 17,084 16,856 \0.0001
Visits to primary care 7,519 4,125 10,001 6,126 0.081 6,302 4,776 10,823 7,898 \0.0001
Visits to medical ward 6,284 9,951 10,021 16,058 0.248 4,098 9,268 6,262 16,296 0.711
Procedures 852 4,111 5,993 18,972 0.453 4,315 14,685 658 3,545 0.289
Filled prescriptions 3,024 2,306 9,732 4,657 \0.0001 2,203 1,551 11,071 6,187 \0.0001
Total costs 17,678 12,946 35,747 30,411 \0.0001 16,918 19,769 28,813 18,779 \0.0001
SD standard deviation
* t test
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packages of devices and aids such as glucose
monitoring, injection needles, and lancets.
Besides filled prescriptions, the increased costs
the year after initiation of insulin were also due
to increased visits to nurses and physicians, to
both medical wards (not statistically
significant), and to primary care.
As can be expected in a diabetes population,
many of the patients in this study had
cardiovascular co-morbidities that might
explain some of the increased costs the year
after initiation of insulin.
There were no major differences in
demographic and clinical characteristics at the
index date when comparing patients with
HbA1c-levels \7.5% or C7.5% at the index
date. Both groups had statistically significant
increased mean annual costs the year after
initiation of insulin compared with the year
before. Interestingly, patients with HbA1c-levels
\7.5% at the index date had higher total
medical costs, both the year before the index
date and the year after, compared with the
HbA1c-level C7.5% group. This might be
explained by the higher proportion of major
cardiovascular events in this group, but the
major increase in costs the year before and after
index date was still explained by an increase in
filled prescriptions. For both groups, costs were
mainly dominated by costs due to health care
visits before the index date, whereas costs due
to filled prescriptions were more prominent in
both groups after the index date.
There are a number of published studies
assessing the health-related costs in patients
treated with insulin. In a German study
published in 1997, estimation of costs for
insulin treated patients was approximately six
times as high as those for patients treated with
OADs, and 30 times as high as for patients
treated with life-style interventions through
specific diets [8]. Another German study by
Liebl et al. [16], estimated direct annual costs
6 months before and after initiation of insulin.
The authors demonstrated that there was a
significant increase in blood glucose devices
during the 6 months after initiation of insulin,
and that the mean 6-month costs increased
from €579 to €961. A more recent study
conducted in Spain [10] in 2011 reported that
mean total healthcare costs per patient
6 months before and after insulin start were
€639 and €1,110, respectively. Mean total costs
6 months after insulin treatment was initiated
included costs of hospitalization (31%), insulin
(16%), primary care (14%), blood glucose
monitoring (14%), specialized care (13%),
OADs (8%), and other diabetes-related
treatments (4%). In a Canadian cost-
effectiveness study from 2011 [11], basic
treatment with metformin was compared with
different second-line treatments added on top
of metformin. The average lifetime cost (direct
healthcare cost) was reported to be $39,924 for
the basic treatment with metformin. The
corresponding cost was $40,669 for metformin
plus SU, $47,191 for metformin plus DPP-4
inhibitor, $47,348 for metformin plus basal
insulin, and $52,367 for metformin plus
biphasic insulin. Hence, the incremental cost
of adding basal insulin or biphasic insulin to the
metformin treatment was $7,424 and $12,443,
respectively.
The results in our study demonstrate that
increased medical healthcare costs the year
before and after initiation of insulin are
comparable with the results of previous studies
[16–19]. Together these data concur that the
initiation of insulin treatment in type 2 diabetic
patients increases medical costs, both in terms
of increased costs due to filled prescriptions of
medications and of devices, but also due to
increased costs due to health care visits. Similar
to the results in the study by Costi et al., our
Diabetes Ther (2013) 4:363–374 371
123
study demonstrated that the highest proportion
of costs the year after the index date were due to
filled prescriptions (given that our study did not
include information on hospitalizations).
Studies have also demonstrated the
relationship between costs and HbA1c level. In
a study by Aagren et al. [20], from 2011, the
relationship between glycemic control,
measured by HbA1c-level, and short-term
healthcare costs was assessed. The population
consisted of commercially insured diabetic
patients (HbA1c level C6%) in the United
States; 34,469 patients with type 2 diabetes
and 1,837 with type 1 diabetes. The study
concluded that the HbA1c-level (and other
factors) significantly correlated with diabetes-
related short-term medical costs for both
patients with type 1 and type 2 diabetes.
Specifically, a 1%-point increase in HbA1c will,
on average, lead to a 4.4% increase in diabetes-
related medical costs for type 2 diabetes. These
results were not comparable with the results in
our study, which is probably explained by the
higher major cardiovascular co-morbidities in
this group. This difference might be more
evident after a longer follow-up period. One
reason for the difference in results compared to
our study might be the selected study
population. In our study, costs were calculated
for patients who had at least 365 days follow-up
both before and after the index date. By using
such an approach, patients who had \365 days
usage of metformin or SU before the index date,
and patients who died before 365 days after the
index date, were excluded from the analysis.
Exclusion of these patients might therefore
have biased the study population by allowing
only patients with less severe disease to be
included in the analysis.
Our study has a number of limitations. First,
the study sample is very small and limited to
one county council and the results might
therefore not be generalizable to other parts of
Sweden. This is probably especially evident in
terms of the sub-group analysis. Secondly,
healthcare utilization is limited to procedures,
outpatient visits at medical wards, and primary
care visits, and does not account for inpatient
and other outpatient care or emergency care.
There was also limited information on
background data for co-morbidities and body
mass index, limiting the possibilities to control
for confounders. Also, when combining the two
data sources, there were some differences
between the different registers that led to
some uncertainties in the data. Furthermore, it
is important to recognize that the full clinical
and economic benefits of an effective diabetes
treatment, such as insulin, in the long run are
not fully accounted for in our study.
CONCLUSION
In summary, despite the small sample size, this
study demonstrates that mean annual medical
costs almost double the year after patients are
initiated on insulin. This increase in costs is
mainly due to increased visits to primary care and
increased drug prescriptions. This study also
demonstrates that costs increase the year after
initiation of insulin regardless of the HbA1c level
at initiation of insulin, which could be a rational
for other treatment options when HbA1c levels
are still below the recommended threshold for
initiation of insulin.
KEY SUMMARY POINTS
• This register-based, retrospective cohort
study was designed to evaluate the
healthcare costs of patients with type 2
diabetes initiating insulin on top of
metformin and/or sulfonylurea (SU) in
Sweden, determine the glycosylated
372 Diabetes Ther (2013) 4:363–374
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hemoglobin (HbA1c)-level at initiation of
insulin, and stratify healthcare costs by this
HbA1c-level.
• Patients were identified from the So¨rmland
county council diabetes register; 100 patients
being prescribed at least one prescription of
metformin and/or SU from 2003-2010, and
later prescribed insulin, were included.
• The mean age was 61 years, 59% of patients
were male. Mean time since diagnosis was
4.1 years and since initiation of insulin was
2.2 years, and the mean HbA1c level at index
date was 8.0%.
• Total mean costs for the whole cohort the
year before initiation of insulin was SEK
17,230 (17,228) and the year after was SEK
31,656 (24,331) (p\0.0001).
• Despite the small study sample, this study
demonstrates that mean annual medical
costs almost double the year after patients
are initiated on insulin; the costs increased
regardless of the HbA1c level at initiation of
insulin, with the largest increase in costs due
to increased filled prescriptions.
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